Contineum Therapeutics (CTNM) Cash from Operations (2023 - 2026)

Contineum Therapeutics' Cash from Operations history runs 4 years deep, the most recent figure standing at 16266000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 12.86% year-over-year to 16266000.0 in Q1 2026; TTM through Mar 2026 was 57166000.0, a 45.53% decrease from a year earlier, with the FY2025 full-year figure at 55312000.0, down 68.4% from the prior year.
• Cash from Operations declined to 16266000.0 in Q1 2026 per CTNM's latest filing, from 13042000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 40674000.0 in Q2 2023 and bottomed at 16266000.0 in Q1 2026.
• The 4-year median for Cash from Operations is 10202000.0 (2024), against an average of 6544153.85.
• Biggest YoY gain for Cash from Operations was 4.69% in 2024; the steepest drop was 120.9% in 2024.
• Year by year, Cash from Operations stood at 10704000.0 in 2023, then increased by 4.69% to 10202000.0 in 2024, then dropped by 27.84% to 13042000.0 in 2025, then decreased by 24.72% to 16266000.0 in 2026.
• Per Business Quant, the three latest CTNM Cash from Operations figures stand at 16266000.0 (Q1 2026), 13042000.0 (Q4 2025), and 12197000.0 (Q3 2025).